Hepatocellular Carcinoma is a major health concern. Currently, this disease is the 3rd leading cause of cancer deaths worldwide with over 500,000 new diagnoses each year. This high incidence of hepatocellular carcinoma development is attributed to environmental insults ranging from exposure to hepatocarcinogens, viral infections, to metabolic disorders. One of the key genetic lesions found in liver cancer is inactivation of the retinoblastoma tumor suppressor (RB) pathway. This pathway is disrupted in most liver tumors via a number of discrete mechanisms including loss of RB gene or deregulation of protein phosphorylation (e.g., p16ink4a loss). Over the last funding cycle we extensively interrogated how RB loss contributes to tumor development. In mouse models, we found that in the absence of carcinogenic stress RB loss is insufficient for tumor development. This is due to extensive compensation of the RB-deficient state and led us to explore unique functions of RB that are not subject to compensatory processes. These analyses demonstrated a novel function of RB in maintaining transcriptional control and cell cycle exit in the presence of specific carcinogenic stresses. Consonantly, RB-deficiency was associated with significantly increased tumor development under such conditions. These combined findings provide the basis for fully understanding how RB-status impinges on transcriptional processes under stress conditions and the specific consequence related to genome integrity driving tumor development (Aim 1). Interestingly, in the course of these studies we found that RB loss is associated with rapid proliferation and progression to advanced tumor grade in mouse models. Molecular analysis of mouse and human HCC tumors revealed that RB plays a complex role on cell cycle and other processes (e.g., adhesion and EMT) that are relevant for disease progression and associate with poor prognosis. The poor survival of HCC is due, in part, to failure to effectively treat advanced disease. Given the key role of RB in tumor etiology/progression, we investigated the ability to activate the RB-pathway as a therapeutic strategy. The findings from these studies indicated that it is possible to therapeutically reinstate the RB-pathway using specific CDK4/6 inhibitors, which are being tested in clinical trials. These combined findings provide the basis fo determining how RB modulates disease progression and how to systematically target the RB-pathway therapeutically in the treatment of HCC (Aim 2).

Public Health Relevance

Hepatocellular Carcinoma (HCC) is a major health concern and is the 3rd leading cause of cancer deaths worldwide. This application is focused on addressing the mechanisms through which HCC arises and new therapeutic approaches based on the RB tumor suppressor pathway. This pathway is frequently altered in human HCC and provides a basis for targeted therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA127387-10
Application #
9325452
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Johnson, Ronald L
Project Start
2007-12-07
Project End
2020-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
10
Fiscal Year
2017
Total Cost
$348,665
Indirect Cost
$93,290
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Knudsen, Erik S; Vail, Paris; Balaji, Uthra et al. (2017) Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res 23:4429-4440
Reed, Christopher; Hutcheson, Jack; Mayhew, Christopher N et al. (2014) RB tumor suppressive function in response to xenobiotic hepatocarcinogens. Am J Pathol 184:1853-9
Hutcheson, Jack; Bourgo, Ryan J; Balaji, Uthra et al. (2014) Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology 60:1231-40
McClendon, A Kathleen; Dean, Jeffry L; Rivadeneira, Dayana B et al. (2012) CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 11:2747-55
Bourgo, Ryan J; Thangavel, Chellappagounder; Ertel, Adam et al. (2011) RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell 43:663-72
DelBove, Jessica; Rosson, Gary; Strobeck, Matthew et al. (2011) Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics 6:1444-53
McClendon, A Kathleen; Dean, Jeffry L; Ertel, Adam et al. (2011) RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology 141:1439-50
Rivadeneira, Dayana B; Mayhew, Christopher N; Thangavel, Chellappagounder et al. (2010) Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 138:1920-30
Reed, C A; Mayhew, C N; McClendon, A K et al. (2009) RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene 28:4434-43